Screening, Assessment, and Pharmacologic Treatment of Mild Cognitive Impairment and Early Alzheimer’s Disease: The Role for Monoclonal Antibodies

References (64)

1. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709–711. PubMed
2. Segal DL, June A, Payne M, et al. Development and initial validation of a self-report assessment tool for anxiety among older adults: the Geriatric Anxiety Scale. J Anxiety Disord. 2010;24(7):709–714. PubMed CrossRef
3. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. (published correction appears in J Am Geriatr Soc. 2019;67(9):1991) J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
4. Lind KE, Hildreth K, Lindrooth R, et al. The effect of direct cognitive assessment in the Medicare annual wellness visit on dementia diagnosis rates. Health Serv Res. 2021;56(2):193–203. PubMed CrossRef
5. Chen YX, Liang N, Li XL, et al. Diagnosis and treatment for mild cognitive impairment: a systematic review of clinical practice guidelines and consensus statements. Front Neurol. 2021;12:719849. PubMed CrossRef
6. Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry. 2018;33(2):379–388. PubMed CrossRef
7. Molnar FJ, Benjamin S, Hawkins SA, et al. One size does not fit all: choosing practical cognitive screening tools for your practice. J Am Geriatr Soc. 2020;68(10):2207–2213. PubMed CrossRef
8. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for cognitive impairment in older adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;323(8):757–763. PubMed CrossRef
9. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922–935. PubMed CrossRef
10. Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the memory impairment screen. Neurology. 1999;52(2):231–238. PubMed CrossRef
11. Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr. 2004;16(3):275–293. PubMed CrossRef
12. Morley JE, Tumosa N. Saint Louis University Mental Status Examination (SLUMS). APA PsycTests; 2002. [Database record]. doi: 10.1037/t27282-000.
13. Borson S, Scanlan JM, Chen P, et al. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–1454. PubMed CrossRef
14. Graf C. The Lawton instrumental activities of daily living scale. Am J Nurs. 2008;108(4):52–62, quiz 62–63. PubMed CrossRef
15. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559–564. PubMed CrossRef
16. Pfeffer RI, Kurosaki TT, Harrah CH Jr, et al. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323–329. PubMed CrossRef
17. Edemekong P, Bomgaars D, et al. Activities of daily living. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2023.
18. Shelkey M, Wallace M. Katz index of independence in activities of daily living. J Gerontol Nurs. 1999;25(3):8–9. PubMed CrossRef
19. Ward A, Tardiff S, Dye C, et al. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Disord Extra. 2013;3(1):320–332. PubMed CrossRef
20. Roberts RO, Knopman DS, Mielke MM, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82(4):317–325. PubMed CrossRef
21. Petersen R, Lopez O, Armstrong M, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. 2018;90(3):126–135.
22. Manly JJ, Jones RN, Langa KM, et al. Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. JAMA Neurol. 2022;79(12):1242–1249. PubMed CrossRef
23. Rajan KB, Weuve J, Barnes LL, et al. Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021;17(12):1966–1975. PubMed CrossRef
24. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286–1294. PubMed CrossRef
25. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–766. PubMed CrossRef
26. Liu PP, Xie Y, Meng XY, et al. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Ther. 2019;4(1):29. PubMed CrossRef
27. Ma C, Hong F, Yang S. Amyloidosis in Alzheimer’s disease: pathogeny, etiology, and related therapeutic directions. Molecules. 2022;27(4):1210. PubMed CrossRef
28. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer’s disease mouse model. Science. 2007;316(5825):750–754. PubMed CrossRef
29. Rapoport M, Dawson HN, Binder LI, et al. Tau is essential to β -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99(9):6364–6369. PubMed CrossRef
30. Therriault J, Pascoal TA, Lussier FZ, et al. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging. Nat Aging. 2022;2(6):526–535. PubMed CrossRef
31. La Joie R, Visani AV, Baker SL, et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732. PubMed CrossRef
32. Largent EA, Grill JD, O’Brien K, et al. Testing for Alzheimer disease biomarkers and disclosing results across the disease continuum. Neurology. 2023;100(21):1010–1019. PubMed CrossRef
33. Korczyn AD. Mixed dementia–the most common cause of dementia. Ann N Y Acad Sci. 2002;977(1):129–134. PubMed CrossRef
34. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. PubMed CrossRef
35. Bucholc M, McClean PL, Bauermeister S, et al. Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: a longitudinal retrospective study. Alzheimers Dement (N Y). 2021;7(1):e12122. PubMed CrossRef
36. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging. 1997;18(suppl):S1–S2. PubMed
37. Chen A, Metzger E, Osser D. Improving pharmacologic management of behavioral and psychological symptoms of dementia (BPSD): an algorithm for real-world care. Am J Geriatr Psychiatry. 2022;30(suppl):S2. CrossRef
38. McDermott CL, Gruenewald DA. Pharmacologic management of agitation in patients with dementia. Curr Geriatr Rep. 2019;8(1):1–11. PubMed CrossRef
39. Gerlach LB, Kales HC. Managing behavioral and psychological symptoms of dementia. Psychiatr Clin North Am. 2018;41(1):127–139. PubMed CrossRef
40. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518. PubMed CrossRef
41. FDA Drug Safety Communication. Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. FDA website. Accessed March 17, 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related
42. Leong C, Alessi-Severini S, Enns MW, et al. Cerebrovascular, cardiovascular, and mortality events in new users of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. J Clin Psychopharmacol. 2017;37(3):332–340. PubMed CrossRef
43. Tampi RR, Bhattacharya G, Marpuri P. Managing behavioral and psychological symptoms of dementia (BPSD) in the era of boxed warnings. Curr Psychiatry Rep. 2022;24(9):431–440. PubMed CrossRef
44. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952–1960. PubMed CrossRef
45. Lloyd EC, Gandhi TN, Petty LA. Monoclonal antibodies for COVID-19. JAMA. 2021;325(10):1015. PubMed CrossRef
46. LiverTox: An Online Resource for Information on Drug-induced Liver Injury. NIDDK website. Accessed March 17, 2023. https://www.niddk.nih.gov/news/archive/2022/livertox-online-resource-information-drug-induced-liver-injury
47. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. PubMed CrossRef
48. Shi M, Chu F, Zhu F, et al. Impact of anti-amyloid-beta monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: a focus on aducanumab and lecanemab. Front Aging Neurosci. 2022;14:870517. PubMed CrossRef
49. Alexander GC, Knopman DS, Emerson SS, et al. Revisiting FDA approval of aducanumab. N Engl J Med. 2021;385(9):769–771. PubMed CrossRef
50. Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13–21. PubMed CrossRef
51. National Coverage Analysis (NCA). Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease. (CAG-00460N) - Proposed Decision Memo. CMS.gov website. Accessed March 17, 2023. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=305
52. Aduhelm. ALZFORUM website. Accessed March 17, 2023. https://www.alzforum.org/therapeutics/aduhelm
53. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. PubMed CrossRef
54. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment. FDA website. Accessed March 17, 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
55. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362–377. PubMed CrossRef
56. Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. PubMed CrossRef
57. Rashad A, Rasool A, Shaheryar M, et al. Donanemab for Alzheimer’s disease: a systematic review of clinical trials. Healthcare (Basel). 2022;11(1):32. PubMed CrossRef
58. Lacorte E, Ancidoni A, Zaccaria V, et al. Safety and efficacy of monoclonal antibodies for alzheimer’s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimers Dis. 2022;87(1):101–129. PubMed CrossRef
59. Robinson JC. Why is aducanumab priced at $56,000 per patient? lessons for drug-pricing reform. N Engl J Med. 2021;385(22):2017–2019. PubMed CrossRef
60. Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478–487. PubMed CrossRef
61. Mafi JN, Leng M, Arbanas JC, et al. Estimated annual spending on aducanumab in the US Medicare program. JAMA Health Forum. 2022;3(1):e214495. PubMed CrossRef
62. Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval | CMS. Accessed Nov 10, 2023. https://www.cms.gov/newsroom/press-releases/statement-broader-medicare-coverage-leqembi-available-following-fda-traditional-approval
63. Cummings J, Lee G, Nahed P, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295. PubMed CrossRef
64. Carrarini C, Russo M, Dono F, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol. 2021;12:644317. PubMed CrossRef